Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada
← catalyst calendarNCT07718139 · readout in 42 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
300estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-28 | actual | When the study began enrolling |
| Primary completion | 2026-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-03-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-07-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Biological: nivolumab
- Biological: pembrolizumab
- Biological: durvalumab
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection.
measured Up to 14 months
Number of participants with major pathological response after neoadjuvant immunotherapy and surgical resection.
measured Up to 14 months
Number of participants with post-operative complications following surgical resection
measured Up to 90 days
Number of participants by surgical resection margin status
measured Up to 14 months
Number of participants by surgical resection type
measured Day 1
Number of participants by surgical approach
measured Day 1
Number of participants with all-cause mortality within 90 days after surgery
measured Up to 90 days
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed